Nature de la demande
Radiation
Arrêt du remboursement suite à un arrêt de commercialisation.
Avis favorable à l’arrêt du remboursement de la spécialité IMBRUVICA (ibrutinib) 140 mg, gélule dans les indications de l’AMM.
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
HwcmBKS81mJ2NVrV
